Physicians are voicing concerns regarding the long-term effects of GLP-1 weight-loss medications on adolescents, despite their documented short-term benefits. GLP-1 usage among teenagers has surged significantly, with a 600 percent increase observed between 2020 and 2023, according to the Journal of the American Medical Association. This trend is driven by rising obesity rates, with over 20 percent of teenagers now classified as obese, a substantial increase from previous decades.
A landmark 2021 trial involving semaglutide, the active ingredient in Wegovy, showed that obese adolescent participants lost an average of 16 percent of their body weight, a result that significantly surpassed lifestyle interventions alone. Beyond weight reduction, these drugs can positively influence health markers such as blood pressure, insulin resistance, and fatty liver disease, potentially altering long-term health trajectories.
Despite these apparent advantages, medical professionals note a lack of comprehensive data on the extended impacts of these drugs on young people. Key areas of uncertainty include how prolonged appetite suppression might affect bone development, nutrient absorption, and brain maturation. Most adolescent trials have followed participants for only one to two years, leaving a gap in understanding the effects over five to 10 years.
Obesity specialists increasingly view GLP-1s as a chronic disease management tool, akin to medications for blood pressure or cholesterol. This perspective suggests that many young patients may need to remain on these drugs indefinitely, even with lifestyle modifications, to prevent weight regain due to potential changes in the body's natural metabolism.
The impact of GLP-1s on adolescents with eating disorders, such as binge eating and bulimia, also presents a complex picture. While some adult patients report a significant reduction in food cravings and compulsive eating, attributed to the drugs enhancing satiety and diminishing food-related reward signals, caution is advised. Not all eating disorders are solely driven by hormonal factors; psychological elements like anxiety, self-destructive compulsions, and body image distortion can play a more significant role, particularly in adolescents. For these individuals, appetite suppression alone may not address underlying triggers and could potentially exacerbate issues.
Physicians emphasize that weight-loss drugs are not a universal solution. While the consideration of GLP-1s may be understandable for adolescents with severe obesity, co-occurring conditions like fatty liver disease or prediabetes, and a history of unsuccessful dieting, careful screening, close medical supervision, and psychological support are crucial. Patients must also be fully informed that obesity is a condition requiring ongoing management.
While GLP-1 medications hold promise for treating overweight adolescents, similar to their efficacy in adults, definitive long-term evidence is still needed. Until more conclusive scientific data is available, the term 'promising' should not be equated with 'proven' when referring to these treatments in children and young adults.